{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T04:03:21Z","timestamp":1746158601268,"version":"3.40.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,30]]},"DOI":"10.7759\/cureus.83278","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T05:06:53Z","timestamp":1746076013000},"source":"Crossref","is-referenced-by-count":0,"title":["Amyloidosis-Related Cardiomyopathy Revealing Waldenstrom Macroglobulinemia: A Case Report"],"prefix":"10.7759","author":[{"given":"Manahil","family":"Tariq","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klara","family":"Lunte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carole","family":"Fleury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damien","family":"Logeart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edouard","family":"Ballout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginie","family":"Siguret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georges","family":"Jourdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2022.2147636","article-title":"Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee","volume":"29","author":"Buxbaum JN","year":"2022","unstructured":"Buxbaum JN, Dispenzieri A, Eisenberg DS, et al.. Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee. Amyloid. 2022, 29:213-9. 10.1080\/13506129.2022.2147636","journal-title":"Amyloid"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13472","article-title":"Patient outcomes in light chain (AL) amyloidosis: the clock is ticking from symptoms to diagnosis","volume":"105","author":"Schulman A","year":"2020","unstructured":"Schulman A, Connors LH, Weinberg J, Mendelson LM, Joshi T, Shelton AC, Sanchorawala V. Patient outcomes in light chain (AL) amyloidosis: the clock is ticking from symptoms to diagnosis. Eur J Haematol. 2020, 105:495-501. 10.1111\/ejh.13472","journal-title":"Eur J Haematol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2023.101040","article-title":"State-of-the-art review on AL amyloidosis in Western Countries: epidemiology, health economics, risk assessment and therapeutic management of a rare disease","volume":"59","author":"Sabinot A","year":"2023","unstructured":"Sabinot A, Ghetti G, Pradelli L, Bellucci S, Lausi A, Palladini G. State-of-the-art review on AL amyloidosis in Western Countries: epidemiology, health economics, risk assessment and therapeutic management of a rare disease. Blood Rev. 2023, 59:101040. 10.1016\/j.blre.2023.101040","journal-title":"Blood Rev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.revmed.2022.04.036","article-title":"Cardiac amyloidosis: state of art in 2022 [Article in French]","volume":"43","author":"Oghina S","year":"2022","unstructured":"Oghina S, Delbarre MA, Poullot E, Belhadj K, Fanen P, Damy T. Cardiac amyloidosis: state of art in 2022 [Article in French]. Rev Med Interne. 2022, 43:537-44. 10.1016\/j.revmed.2022.04.036","journal-title":"Rev Med Interne"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1159\/000506617","article-title":"When to suspect a diagnosis of amyloidosis","volume":"143","author":"Vaxman I","year":"2020","unstructured":"Vaxman I, Gertz M. When to suspect a diagnosis of amyloidosis. Acta Haematol. 2020, 143:304-11. 10.1159\/000506617","journal-title":"Acta Haematol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.13701","article-title":"Thromboembolism and bleeding in systemic amyloidosis: a review","volume":"9","author":"Nicol M","year":"2022","unstructured":"Nicol M, Siguret V, Vergaro G, et al.. Thromboembolism and bleeding in systemic amyloidosis: a review. ESC Heart Fail. 2022, 9:11-20. 10.1002\/ehf2.13701","journal-title":"ESC Heart Fail"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2016.07.001","article-title":"Cardiac amyloidosis: how to recognize them and manage them? [Article in French]","volume":"45","author":"Bodez D","year":"2016","unstructured":"Bodez D, Galat A, Guellich A, et al.. Cardiac amyloidosis: how to recognize them and manage them? [Article in French]. Presse Med. 2016, 45:845-55. 10.1016\/j.lpm.2016.07.001","journal-title":"Presse Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000068314.02595.B2","article-title":"Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis","volume":"107","author":"Palladini G","year":"2003","unstructured":"Palladini G, Campana C, Klersy C, et al.. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation. 2003, 107:2440-5. 10.1161\/01.CIR.0000068314.02595.B2","journal-title":"Circulation"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/eci.12234","article-title":"Kidney function crucially affects B-type natriuretic peptide (BNP), N-terminal proBNP and their relationship","volume":"44","author":"Takase H","year":"2014","unstructured":"Takase H, Dohi Y. Kidney function crucially affects B-type natriuretic peptide (BNP), N-terminal proBNP and their relationship. Eur J Clin Invest. 2014, 44:303-8. 10.1111\/eci.12234","journal-title":"Eur J Clin Invest"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2016.08.013","article-title":"Monoclonal IgM-related AL amyloidosis","volume":"29","author":"Milani P","year":"2016","unstructured":"Milani P, Merlini G. Monoclonal IgM-related AL amyloidosis. Best Pract Res Clin Haematol. 2016, 29:241-8. 10.1016\/j.beha.2016.08.013","journal-title":"Best Pract Res Clin Haematol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury JD","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, et al.. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022, 36:1703-19. 10.1038\/s41375-022-01613-1","journal-title":"Leukemia"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0001","article-title":"Waldenstr\u00f6m macroglobulinemia\/lymphoplasmacytic lymphoma, version 2.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Kumar SK","year":"2024","unstructured":"Kumar SK, Callander NS, Adekola K, et al.. Waldenstr\u00f6m macroglobulinemia\/lymphoplasmacytic lymphoma, version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024, 22:e240001. 10.6004\/jnccn.2024.0001","journal-title":"J Natl Compr Canc Netw"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl109","article-title":"Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154\/CD40 signaling","volume":"17","author":"Tournilhac O","year":"2006","unstructured":"Tournilhac O, Santos DD, Xu L, et al.. Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154\/CD40 signaling. Ann Oncol. 2006, 17:1275-82. 10.1093\/annonc\/mdl109","journal-title":"Ann Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bulcan.2022.08.012","article-title":"Waldenstr\u00f6m disease: news and perspectives in 2022 [Article in French]","volume":"110","author":"Bouclet F","year":"2023","unstructured":"Bouclet F, Krzisch D, Leblond V, et al.. Waldenstr\u00f6m disease: news and perspectives in 2022 [Article in French]. Bull Cancer. 2023, 110:88-100. 10.1016\/j.bulcan.2022.08.012","journal-title":"Bull Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/nature09121","article-title":"Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR\/IL-1R signalling","volume":"465","author":"Lin SC","year":"2010","unstructured":"Lin SC, Lo YC, Wu H. Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR\/IL-1R signalling. Nature. 2010, 465:885-90. 10.1038\/nature09121","journal-title":"Nature"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.14670\/HH-19.299","article-title":"SDF-1 and CXCR4 in normal and malignant hematopoiesis","volume":"19","author":"Juarez J","year":"2004","unstructured":"Juarez J, Bendall L. SDF-1 and CXCR4 in normal and malignant hematopoiesis. Histol Histopathol. 2004, 19:299-309. 10.14670\/HH-19.299","journal-title":"Histol Histopathol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01102-3","article-title":"CXCR4 in Waldenstr\u00f6m's macroglobulinema: chances and challenges","volume":"35","author":"Kaiser LM","year":"2021","unstructured":"Kaiser LM, Hunter ZR, Treon SP, Buske C. CXCR4 in Waldenstr\u00f6m's macroglobulinema: chances and challenges. Leukemia. 2021, 35:333-45. 10.1038\/s41375-020-01102-3","journal-title":"Leukemia"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.14797\/mdcvj.1050","article-title":"Cardiac amyloidosis treatment","volume":"18","author":"Stern LK","year":"2022","unstructured":"Stern LK, Patel J. Cardiac amyloidosis treatment. Methodist Debakey Cardiovasc J. 2022, 18:59-72. 10.14797\/mdcvj.1050","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000725","article-title":"How I treat Waldenstr\u00f6m macroglobulinemia","volume":"134","author":"Dimopoulos MA","year":"2019","unstructured":"Dimopoulos MA, Kastritis E. How I treat Waldenstr\u00f6m macroglobulinemia. Blood. 2019, 134:2022-35. 10.1182\/blood.2019000725","journal-title":"Blood"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01762-3","article-title":"Diagnostics in Waldenstr\u00f6m's macroglobulinemia: a consensus statement of the European Consortium for Waldenstr\u00f6m's Macroglobulinemia","volume":"37","author":"Dogliotti I","year":"2023","unstructured":"Dogliotti I, Jim\u00e9nez C, Varettoni M, et al.. Diagnostics in Waldenstr\u00f6m's macroglobulinemia: a consensus statement of the European Consortium for Waldenstr\u00f6m's Macroglobulinemia. Leukemia. 2023, 37:388-95. 10.1038\/s41375-022-01762-3","journal-title":"Leukemia"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/344236-amyloidosis-related-cardiomyopathy-revealing-waldenstrom-macroglobulinemia-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T05:06:54Z","timestamp":1746076014000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/344236-amyloidosis-related-cardiomyopathy-revealing-waldenstrom-macroglobulinemia-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.83278","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,30]]}}}